Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis

Project: Research project

Project Details

Description

Osteoarthritis (OA) is a debilitating disease of the joints involving progressive cartilage degeneration due to aberrant articular chondrocyte hypertrophy (CH), with no disease modifying therapy available. Articular chondrocytes are rich with GPCRs whose signaling regulate CH. The pathologic role of GPCR signaling is recognized in other diseases and represents an attractive target for novel therapies. However, the role of GPCR signaling in OA remain unknown. Here, we propose using genetic mouse models and small molecule inhibitors including an FDA-approved drug to modify GPCR signaling, inhibit CH, and promote cartilage protection and possible regeneration in OA. Aiming at discovering novel OA therapy.
StatusActive
Effective start/end date2/21/1912/31/22

Funding

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $337,260.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $337,260.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $303,534.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.